1486-51-7

Basic information

• Product Name: 4-BENZYLOXYBENZOIC ACID
• Synonyms: AKOS BB-8602;AKOS BBB/285;ASISCHEM A95731;ART-CHEM-BB B025595;p-(benzyloxy)benzoic acid;4-Benzyloxybenzoicacid99%;4-Benzyloxybenzoicacid 99%;4-Benzyloxybenzoic acid, 98+%
• CAS NO: 1486-51-7
• Molecular Formula: C₁₄H₁₂O₃
• Molecular Weight: 228.24
• EINECS: 216-066-0
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic Acids (Building Blocks for Liquid Crystals);Bifunctional Compounds (Building Blocks for Liquid Crystals);Building Blocks for Liquid Crystals;Functional Materials;C13 to C42+;Carbonyl Compounds;Carboxylic Acids
• Mol File: 1486-51-7.mol
• Article Data: 105

Chemical Properties

• Melting Point: 189-192 °C(lit.)
• Boiling Point: 396.277 °C at 760 mmHg
• Flash Point: 152.309 °C
• Appearance: /
• Density: 1.222
• Vapor Pressure: 5.44E-07mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: very faint turbidity in Pyridine
• PKA: 4.46±0.10(Predicted)
• BRN: 2111640
• CAS DataBase Reference: 4-BENZYLOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXYBENZOIC ACID(1486-51-7)
• EPA Substance Registry System: 4-BENZYLOXYBENZOIC ACID(1486-51-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1486-51-7(Hazardous Substances Data)

Usage

Description

4-Benzyloxybenzoic acid is a substituted benzoic acid derivative, characterized by the presence of a benzyloxy group attached to the 4-position of the benzene ring. It can be synthesized through the benzylation of 4-hydroxybenzoic acid using benzyl bromide as a reagent. This organic compound serves as a key intermediate in the synthesis of various complex molecules and has potential applications in different industries.

Uses

Used in Chemical Synthesis:
4-Benzyloxybenzoic acid is used as a key intermediate in the chemical synthesis of more complex organic compounds. Its unique structure allows for further functionalization and modification, making it a versatile building block in organic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Benzyloxybenzoic acid is used as a starting material for the preparation of various pharmaceutical compounds. One such application is in the synthesis of 1,3-phenylene bis(4-benzyloxybenzoate), which may have potential therapeutic applications.
Used in the Synthesis of Chiral Compounds:
4-Benzyloxybenzoic acid is also utilized in the preparation of chiral compounds, such as (-)-(2R,3R)-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)-phenyl]chroman-3-yl-(4-benzyloxy)benzoate. These chiral molecules have significant importance in the development of enantiomerically pure drugs, as they can exhibit different biological activities and pharmacological properties.

InChI:InChI=1/C14H12O3/c15-14(16)12-6-8-13(9-7-12)17-10-11-4-2-1-3-5-11/h1-9H,10H2,(H,15,16)/p-1

Upstream product

• 100-39-0 benzyl bromide 
• 99-96-7 4-hydroxy-benzoic acid 
• 123-91-1 1,4-dioxane 
• 865-47-4 potassium tert-butylate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 584-08-7 potassium carbonate 
• 100-44-7 benzyl chloride 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 56441-55-5 ethyl 4-(benzyloxy)benzoate 
• 32122-11-5 4-benzyloxy-benzoic acid methyl ester 
• 6373-46-2 p-benzyloxyaniline 
• 124-38-9 carbon dioxide 
• 1589-82-8 phenylmagnesium bromide 
• 58327-40-5 α-Hydroxy-4-(phenylmethoxy)benzeneacetonitrile 

Downstream Products

• 110482-77-4 4-Benzyloxy-benzoic acid 4-((S)-1-methyl-heptyloxy)-phenyl ester 
• 183106-07-2 C₄₄H₅₄O₆ 
• 1002105-03-4 (S)-1-methylheptyl 4-(4-benzyloxyphenylcarbonyloxy)benzoate 
• 178267-82-8 (S,S)-tetradecane-2,13-diyl bis(4-benzyloxybenzoate) 
• 183106-05-0 C₄₃H₅₂O₆ 
• 591228-79-4 {3-[(4-benzyloxy-benzoyl)-ethyl-amino]-propyl}-(1-cyclohexylmethyl-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 858941-89-6 4-n-hexyloxyphenyl 4-[3-(4-benzyloxybenzoyloxy)benzoyloxy]benzoate 

Relevant articles and documents

Preparation and mesomorphic properties of highly fluorinated materials incorporating S-ethyl-lactate

The synthesis of three different chiral short molecular weight compounds have been reported. The overall compounds incorporate a linear perfluorinated tail and S-ethyl-Iactate as chiral moiety. Each compound differ to the other by one molecular parameter: a spacer carbonyloxy or oxycarbonylmethoxy or by the presence or not of an ester function between the two aromatic rings of the mesogenic core. The synthesis have been carried out from 2-F-hexylethyliodide or 2-F-hexylethanol. The mesomorphic properties have been characterized by light microscopy and by differential thermal analysis showing the peculiar effect of the spacer. The two biphenyl derivatives exhibit liquid crystal properties over a wide temperature range. The mesophase for both compounds is smectic of type A. However, the introduction of an ester function in the core contribute to enhance the melting temperature and suppress the liquid crystal behavior.

Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors

The hedgehog (Hh) signaling pathway is involved in diverse aspects of cellular events. Aberrant activation of Hh signaling pathway drives oncogenic transformation for a wide range of cancers, and it is therefore a promising target in cancer therapy. In the principle of association and ring-opening, we designed and synthesized a series of Hh signaling pathway inhibitors with phenyl imidazole scaffold, which were biologically evaluated in Gli-Luc reporter assay. Compound 25 was identified to possess high potency with nanomolar IC50, and moreover, it preserved the inhibition against wild-type and drug-resistant Smo-overexpressing cells. A molecular modeling study of compound 25 expounded its binding mode to Smo receptor, providing a basis for the further structural modification of phenyl imidazole analogs.

Cannabidiol derivative, preparation method and application thereof

The invention discloses a cannabidiol derivative, a preparation method and application thereof, and belongs to the technical field of medicinal chemistry, wherein the cannabidiol derivative is obtained by taking cannabidiol as a main body through a synthesis means, and an anti-tumor activity determination result shows that the cannabidiol derivative prepared by the invention has an inhibition effect on lung cancer cell strains, human breast cancer cell strains, nasopharynx cancer and drug-resistant strains thereof.